Imclone (IMCL) is seeing four times its normal trading volume. More than 22,000 calls and 8,566 puts have traded on the day. Shares are up 27 cents to $43.27 after Leerink Swann (?) started the stock with an outperform rating and a $55 price target. Firm believes that company’s pipeline will get better recognition and that Erbitux can generate sustained growth in the next few years. ImClone also presents at the five-day ASCO Annual Meeting in Chicago, which started today.